Drug · CHEMBL550
PILOCARPINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PILOCARPINE. Drugs and targets, record CHEMBL550. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL550
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CHRM1 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M1 agonist | AGONIST | https://conductscience.org/library/genes/1128 |
| CHRM3 | Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M3 agonist | AGONIST | https://conductscience.org/library/genes/1131 |
Source ChEMBL
Diseases13
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 13Source Open Targets
See all 13 diseasesTrials48
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04983589 | A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily | Phase 3 | 230 | 2023-03-21 | pilocarpine | Its name | ClinicalTrials.gov |
| NCT00343382 | Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer | Phase 3 | 201 | 2014-09-30 | pilocarpine | Its name | ClinicalTrials.gov |
| NCT00656513 | Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer | Phase 2/3 | 196 | 2017-08-21 | pilocarpine | Its name | ClinicalTrials.gov |
| NCT04675151 | Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia | Phase 2 | 150 | 2023-08-02 | pilocarpine | Its name | ClinicalTrials.gov |
| NCT04837482 | A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age | Phase 3 | 43 | 2024-10-10 | pilocarpine | Its name | ClinicalTrials.gov |
| NCT00762645 | Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG) | Phase 4 | 30 | 2010-03-15 | pilocarpine | Its name | ClinicalTrials.gov |
| NCT02754570 | The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure | 27 | 2019-11-07 | pilocarpine | Its name | ClinicalTrials.gov | |
| NCT01690052 | Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva | 15 | 2014-08-06 | pilocarpine | Its name | ClinicalTrials.gov | |
| NCT02935894 | Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat | 14 | 2018-06-01 | pilocarpine | Its name | ClinicalTrials.gov | |
| NCT05238233 | Wearing-Off Period of Pharmacological Dilation and Anisocoria | Phase 4 | 11 | 2023-03-07 | pilocarpine | Its name | ClinicalTrials.gov |
1 to 10 of 48
See all 48 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| AGN-190584 vs Vehicle: deaths from any cause | 0 of 114 | 0 of 116 | 230 | NCT04983589 | Trial comparisons |
| AGN-190584 vs Vehicle: serious adverse events | 0 of 114 | 0 of 116 | 230 | NCT04983589 | Trial comparisons |
| AGN-190584 vs Vehicle: Number of Participants With Adverse Events | 32 of 43 | 8 of 43 | 86 | NCT04837482 | Trial comparisons |
| Pilocarpine Group vs PGA Monotherapy: deaths from any cause | 0 of 27 | 0 of 27 | 54 | NCT02754570 | Trial comparisons |
| Pilocarpine Group vs PGA Monotherapy: serious adverse events | 0 of 27 | 0 of 27 | 54 | NCT02754570 | Trial comparisons |
| Travoprost 0.004% (Travatan) vs Pilocarpine 1%: Number of Patients With Peripheral Anterior Synechiae (PAS) | 0 of 16 | 0 of 14 | 30 | NCT00762645 | Trial comparisons |
| Travoprost 0.004% (Travatan) vs Pilocarpine 1%: serious adverse events | 0 of 16 | 0 of 14 | 30 | NCT00762645 | Trial comparisons |
| Cevimeline Then Pilocarpine (Intervention 1) vs Pilocarpine Then Cevimeline (Intervention 2): deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT01690052 | Trial comparisons |
| Cevimeline Then Pilocarpine (Intervention 1) vs Pilocarpine Then Cevimeline (Intervention 2): serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT01690052 | Trial comparisons |
Papers from its trials23
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL550
GET https://conductscience.org/api/drugs/v1/CHEMBL550/trials?page=2